Recently, there has been much discussion among clinicians regarding the safe, efficacious, and optimal use of topical antibiotic-retinoid preparations in the management of acne. More specifically, clinicians are concerned about antimicrobial resistance as it relates to Propionibacterium acnes (P acnes), and the topical antibiotics used to treat this pathogen. Additionally, there has been discussion about the compatibility of topical antibiotic agents when used in combination with other treatments.
Master Clinicians Present™ ACT On Acne Perspectives on P acnes: Resistance and Compatibility in the Use of Topical Combination Agents in the Management of Moderate-to-Severe Acne is a dialogue between national thought leaders — addressing many of the issues being discussed by dermatologists in the United States today. This podcast provides a unique opportunity for clinicians to "listen in" as the experts present their views on P acnes and optimal treatments for combating resistance and effectively treating acne.
Assessment of Need
Acne, as one of the most prevalent skin conditions, affects 85% of individuals 12 to 24 years of age. If left untreated, acne can have serious physical and psychological consequences, including permanent scarring, disfigurement, anxiety, and depression.
The pathogenesis of acne is multifactorial, encompassing hyperkeratosis and abnormal desquamation of the follicular epithelium, proliferation of the bacteria P acnes, androgen-induced hypertrophy of the sebaceous glands, and inflammation.
P acnes, a contributing factor to the development of inflammatory acne in patients, can be present in high numbers in the sebaceous follicles. Antibiotic treatment for acne, which decreases the presence of P acnes in the skin, has been used for over 40 years. Since the 1970s, antibiotic resistance of P acnes has increased steadily.
Physicians have begun to use combination therapies to combat the antibiotic-resistant P acnes and target the pathophysiologic variables of acne that has been shown to improve outcomes. This approach may encompass the use of oral antibiotics and topical agents such as antibiotics, antimicrobials, and retinoic-acidlike agents, along with other topical combination products.
Disclosure Statement
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Complete faculty disclosure will be provided to program participants prior to the beginning of the activity.
Learning Objectives
At the completion of this podcast, participants should be able to:
• Discuss current and evolving data regarding the use of topical combination agents in the management of acne
• Provide perspective on issues related to antibiotic resistance, side effect profiles, and product stability
• Employ an evidence-based approach to the optimal use of topical combinations for the treatment of acne
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and SynerMed® Communications. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Penn State College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.